END-OF-YEAR DRIVE: HOW YOU CAN HELP SUPPORT LOCAL NEWS

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

724.78 +1.98 (+0.27%)
Streaming Delayed Price Updated: 10:45 AM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
News headline image
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss ↗
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
Via Benzinga
News headline image
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
News headline image
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent ↗
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
Via Benzinga
News headline image
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today ↗
 
Via Benzinga
News headline image
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗
 
Via Benzinga
News headline image
Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on REGN Options ↗
 
Via Benzinga
News headline image
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
News headline image
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What the Options Market Tells Us About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry ↗
 
Via Benzinga
News headline image
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
News headline image
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays. 
Via MarketBeat
Topics ETFs Earnings
News headline image
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on REGN Options ↗
 
Via Benzinga
News headline image
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today ↗
 
Via Benzinga
News headline image
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs ↗
Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects... 
Via Benzinga
News headline image
Should You Buy the Dip on This Top Growth Stock? ↗
The biotech needs to overcome an issue most drugmakers face at some point. 
Via The Motley Fool
News headline image
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio? ↗
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
Via Benzinga
News headline image
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review ↗
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus. 
Via Investor's Business Daily
Topics Stocks
News headline image
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease ↗
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... 
Via Benzinga
News headline image
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
Via Investor's Business Daily
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article